acetyl l carnitine cfs Conceptual foundations of acetylcarnitine supplementation in neuropsychiatric long COVID syndrome: a narrative review | European Archives of Psychiatry and Clinical Neuroscience Acetyl L-Carnitine - FTI Supplements

Funding This work was supported by the Carlos III Health Institute (ISCIII) (Grant Number PI19/0838), the European Regional Development Fund, and the Ministry of Education of the Valencian Regional Government (Grant Number PROMETEO/2019/027)

Conditions Locations Treatment Type Trial Phase Trial Status Paid Participation Trial Details Key Eligibility Criteria 1000 Participants Needed Trial Details Key Eligibility Criteria 1020 Participants Needed Trial Details Key Eligibility Criteria 50 Participants Needed Trial Details Key Eligibility Criteria 33 Participants Needed Trial Details Key Eligibility Criteria 60 Participants Needed Trial Details Key Eligibility Criteria 100 Participants Needed Trial Details Key Eligibility Criteria 23 Participants Needed Trial Details Key Eligibility Criteria 36 Participants Needed Trial Details Key Eligibility Criteria 80 Participants Needed Trial Details Key Eligibility Criteria 154 Participants Needed Trial Details Key Eligibility Criteria 50 Participants Needed Trial Details Key Eligibility Criteria 140 Participants Needed Trial Details Key Eligibility Criteria 100 Participants Needed Trial Details Key Eligibility Criteria 60 Participants Needed Trial Details Key Eligibility Criteria 140 Participants Needed Trial Details Key Eligibility Criteria 28 Participants Needed Trial Details Key Eligibility Criteria 80 Participants Needed Trial Details Key Eligibility Criteria 134 Participants Needed Trial Details Key Eligibility Criteria 20 Participants Needed Trial Details Key Eligibility Criteria 60 Participants Needed "I've tried several different SSRIs over the past 23 years with no luck

In a randomized controlled trial comparing the effect of aromatase inhibitor and GnRH agonist on UF, it was found that both interventions are able to reduce the myoma volume and symptoms

Parkinsons disease, or PD, is a neurodegenerative disorder of the central nervous system

Characterization and quantification by HPLC-tandem mass spectrometry